|
|
|
| |
|
|
| |
Testing platforms for decentralized, near-patient, and critical care applications |
|
|
|
| |
 Precision Phase 1 Trials for Clinical Confidence
Pharmaron’s Clinical Pharmacology Center delivers high-quality Phase 1 studies with rapid start-up, exceptional recruitment, and long-term retention. Purpose-built First-in-Human and 14C-hADME suites, expert Principal Investigator oversight, and integrated clinical services ensure robust, reliable data to support confident decision-making in early clinical and point-of-care development.
| |
|
|
| |  | | |  A new blood marker reflects the extent of brain injury after an ischemic stroke and can predict patient outcomes months to years later. | | | | |  For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease prevention or slowing, rather than recovery. | | | | |  Today, the ACCESS-AD consortium is announcing the launch of a transformative European initiative that will accelerate the implementation of scientific innovations for Alzheimer's disease (AD) management in real-world health systems. | | | | |  The SleepFM model reveals how sleep analysis can predict disease risk, offering insights into sleep's role as a vital health indicator for early intervention. | | | | |  Let's be clear: The primary reason to be vaccinated against shingles is that two shots provide at least 90% protection against a painful, blistering disease that a third of Americans will suffer in their lifetimes, one that can cause lingering nerve pain and other nasty long-term consequences. | |
|
|
| | | How would you rate today's newsletter?
| |
|
|
| | |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
|
|
